Why the study?
Patients with ACS remain at high risk for recurrent ischaemic and bleeding events, but the comparative impact of these adverse events on quality of life required quantification.
Do recurrent ischaemic and bleeding events reduce quality of life in patients with acute coronary syndrome?
Do recurrent ischaemic and bleeding events reduce quality of life in patients with acute coronary syndrome?
Both recurrent ischaemic and bleeding events independently reduce quality of life at 12 months in ACS patients, emphasizing the importance of balancing these risks in clinical management.
Answers are grounded in this paper and cite their sources.
Recurrent events were associated with worse QoL in ACS; hypothesis-generating for trials balancing ischaemic-bleeding risks.
OBJECTIVE: Patients with acute coronary syndrome (ACS) remain at high risk for recurrent ischaemic and bleeding events during follow-up. Our study aimed to quantify and compare the impact of these adverse events on quality of life (QoL). METHODS: Data from patients with ACS prospectively enrolled in the FORCE-ACS registry between January 2015 and December 2019 were used for this study. The primary ischaemic and bleeding events of interest were hospital readmission for ACS and Bleeding Academic Research Consortium type 2 or 3 bleeding during 12 months follow-up. QoL was measured using the EQ-5D Visual Analogue Scale (VAS) score and the 12-item Short Form Survey version 2 derived Physical Component Summary (PCS) and Mental Health Component Summary (MCS) scores at 12 months follow-up. RESULTS: In total, 3339 patients (mean age 66.8 years, 27.9% women) were included. During follow-up, ischaemic events occurred in 202 patients (6.0%) and bleeding events in 565 patients (16.9%). After adjustment for demographic and clinical characteristics, ischaemic events remained independently associated with lower QoL regardless of metric used. Bleeding was also independently associated with lower EQ-5D VAS and PCS scores, but not with a lower MCS score. The QoL decrement associated with ischaemic events was numerically larger than the decrement associated with bleeding. CONCLUSIONS: Ischaemic and bleeding events remain prevalent and are independently associated with lower QoL at 12 months follow-up in patients previously admitted for ACS. The incidence and impact of these adverse events should be considered when balancing individual ischaemic and bleeding risks.
No takes yet. Share an insight, caveat, or question.
Sangen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: